Latex allergy

Summary

Latex allergy (MONDO:0000807) is a disease and 3 clinical trials. A subtype of allergic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	latex allergy
Mondo ID	MONDO:0000807
MeSH	D020315
DOID	DOID:0060532
SNOMED CT	300916003
UMLS	C0577628
MedGen	107909
Is cancer (heuristic)	no

Disease family

This is a subtype of allergic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › hypersensitivity reaction disease › allergic disease › latex allergy

Related subtypes (11): allergic respiratory disease, drug allergy, gastrointestinal allergy, atopic eczema, atopic IgE-mediated allergic disorder, eye allergy, vulvovaginitis, allergic seminal, allergic otitis media, alpha-gal syndrome, venom allergy, food allergy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01133288	Not specified	TERMINATED	Yulex Glove Prospective Study in Spina Bifida
NCT02575053	Not specified	COMPLETED	Safety of a Powder-free Latex Allergy Protocol in the Operating Theatre: A Prospective, Observational Cohort Study
NCT05515276	Not specified	COMPLETED	The COVID-19 Pandemic Process Increase Latex Glove Use and Latex Allergy Complaints in Hospital Nurses? Survey Study